<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-26391" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Osteogenic Sarcoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Arora</surname>
            <given-names>Rahul D.</given-names>
          </name>
          <aff>Delhi State Health Mission</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shaikh</surname>
            <given-names>Hira</given-names>
          </name>
          <aff>University of Cincinnati Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rahul Arora declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hira Shaikh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-26391.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Osteogenic sarcoma is the most common primary malignant bone tumor with an annual incidence of 900 cases in the United States. This activity reviews the role of the interprofessional team in history and physical examination, laboratory evaluation, and management. It also includes a review of the recent advances in the management of this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Summarize the etiological factors of osteogenic sarcoma.</p></list-item><list-item><p>Review the evaluation of osteogenic sarcoma.</p></list-item><list-item><p>Outline the management of osteosarcoma.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26391&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26391">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-26391.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Osteogenic sarcoma (osteosarcoma) is the most common primary tumor of the bone, found most commonly in the extremities, with a bimodal age distribution.<xref ref-type="bibr" rid="article-26391.r1">[1]</xref> Approximately 75% of cases present&#x000a0;before the age of 25 years and are majorly primary (without attributing risk factor). A late peak is seen after the age of 50 years (peaking at 70 years), secondary&#x000a0;to Paget&#x02019;s disease and irradiation.<xref ref-type="bibr" rid="article-26391.r2">[2]</xref>&#x000a0;</p>
        <p>High-grade conventional intramedullary&#x000a0;osteosarcoma is the most common subtype.<xref ref-type="bibr" rid="article-26391.r3">[3]</xref> It is a biologically complex and aggressive tumor with a propensity to involve the growing metaphysis of the extremity bones, usually adjacent to the physes with the greatest growth (lower femur, upper tibia, and the upper end of the humerus).<xref ref-type="bibr" rid="article-26391.r4">[4]</xref></p>
        <p>Complete surgical extirpation is usually the treatment of choice if localized.<xref ref-type="bibr" rid="article-26391.r5">[5]</xref> Around 10% to 20% have evidence of metastases at presentation, the&#x000a0;most common site being the lungs.<xref ref-type="bibr" rid="article-26391.r6">[6]</xref> Occult micrometastasis at diagnosis are presumed to be more frequent, considering that over 80% patients present with metastasis despite local control before the advent of chemotherapy. With the routine use of chemotherapy, approximately&#x000a0;two-thirds of children and adolescents will achieve long-term cure.<xref ref-type="bibr" rid="article-26391.r7">[7]</xref></p>
      </sec>
      <sec id="article-26391.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Risk factors for the development of osteosarcoma include previous irradiation, Paget&#x02019;s disease of the bone, and inherited syndromes caused by&#x000a0;abnormalities in DNA repair mechanisms such as Li-Fraumeni syndrome (LFS), Wermer&#x02019;s syndrome, Rothmund Thompson syndrome, and familial retinoblastoma syndrome.<xref ref-type="bibr" rid="article-26391.r8">[8]</xref>&#x000a0;Retinoblastoma (associated with familial retinoblastoma syndrome) and p53 (associated with LFS) tumor suppressor genes are reported to be&#x000a0;mutated in 67 and 90 percent of the cases, respectively.<xref ref-type="bibr" rid="article-26391.r9">[9]</xref></p>
        <p>Mutations in RAS associated family member 1a, which is a major downstream effector molecule of K-ras, has been shown to be hypermethylated in tumor cell lines.<xref ref-type="bibr" rid="article-26391.r10">[10]</xref>&#x000a0;PI3K/mTOR pathway, a downstream effector of the Ras pathway, has also been shown to be mutated in osteosarcoma.<xref ref-type="bibr" rid="article-26391.r11">[11]</xref>&#x000a0;</p>
        <p>Additionally, pathways such as&#x000a0;Notch signaling via Notch 1-4 phenotype&#x000a0;involved in morphogenesis and proliferation&#x000a0;have&#x000a0;been implicated in the pathogenesis.<xref ref-type="bibr" rid="article-26391.r12">[12]</xref><xref ref-type="bibr" rid="article-26391.r13">[13]</xref>&#x000a0;Epigenetic changes involving the inhibition of histone deacetylases have also been reported.<xref ref-type="bibr" rid="article-26391.r14">[14]</xref>&#x000a0;Inhibitors of aurora kinases and DNA methyltransferases have also shown some promise as potential&#x000a0;treatment options.<xref ref-type="bibr" rid="article-26391.r15">[15]</xref></p>
      </sec>
      <sec id="article-26391.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Approximately 900 cases of osteosarcoma are diagnosed in the United States of America every year.<xref ref-type="bibr" rid="article-26391.r14">[14]</xref>&#x000a0;Osteosarcomas constitute less than 1% of&#x000a0;all newly diagnosed tumors in adults, and close to 4% of all newly diagnosed cases in children.<xref ref-type="bibr" rid="article-26391.r4">[4]</xref>&#x000a0;It is the most common tumor in the adolescent age group, after the exclusion of haematolymphoid malignancies, with a predilection for males.<xref ref-type="bibr" rid="article-26391.r6">[6]</xref>&#x000a0;</p>
        <p>About 20 percent of the cases present with metastatic disease at presentation. The most common site of distant spread is the lung (60-70 percent), followed by bone (either skip or distant) in 20-30 percent cases.</p>
        <p>Amongst osteosarcomas, which originate along the cortex or the periosteum, parosteal osteosarcoma is the most common juxtacortical lesion, constituting 1 to&#x000a0;6 percent of the cases.<xref ref-type="bibr" rid="article-26391.r16">[16]</xref>&#x000a0;The Ilium is the most common bone in the pelvis to be involved by osteosarcoma.<xref ref-type="bibr" rid="article-26391.r17">[17]</xref></p>
        <p>Vertebral osteosarcomas comprise 4&#x000a0;to 15 percent of primary spinal tumors and 1&#x000a0;to 3 percent of osteosarcomas.<xref ref-type="bibr" rid="article-26391.r18">[18]</xref>&#x000a0;High-grade craniofacial osteosarcomas develop in older age,&#x000a0;in contrast to conventional osteosarcomas.<xref ref-type="bibr" rid="article-26391.r19">[19]</xref></p>
      </sec>
      <sec id="article-26391.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Rapid bone growth has been shown to predispose to the development of this tumor, as is evidenced by the involvement of the bone in proximity to the growing physes and the fact that it is seen to occur more commonly at the time of the pubertal growth spurt.<xref ref-type="bibr" rid="article-26391.r4">[4]</xref></p>
      </sec>
      <sec id="article-26391.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The most common type of osteosarcoma is high-grade, intramedullary, conventional osteosarcoma.&#x000a0;This is further divided into&#x000a0;histological subtypes are osteoblastic, chondroblastic, and fibroblastic varieties depending on the predominant cellular component.<xref ref-type="bibr" rid="article-26391.r20">[20]</xref>&#x000a0;In addition to these three subcategories, there exist variants of conventional&#x000a0;osteosarcoma that confer worse prognosis&#x000a0;&#x02013; telangiectatic, small cell, multifocal, and undifferentiated high-grade pleomorphic sarcoma.<xref ref-type="bibr" rid="article-26391.r4">[4]</xref></p>
        <p>In contrast to the conventional osteosarcomas (high grade) that are intramedullary, two indolent variants arising from the&#x000a0;surface of the cortex include periosteal osteosarcomas (intermediate grade)&#x000a0;that arise from the inner cambial layer and parosteal osteosarcomas (low-grade) that arise from&#x000a0;the&#x000a0;outer fibrous layer of the periosteum, respectively.<xref ref-type="bibr" rid="article-26391.r21">[21]</xref><xref ref-type="bibr" rid="article-26391.r22">[22]</xref></p>
        <p>Osteosarcoma is a mesenchymal neoplasm that produces osteoid as well as the woven bone matrix.<xref ref-type="bibr" rid="article-26391.r23">[23]</xref>&#x000a0;Production of the osteoid matrix is the "<italic toggle="yes">sina qua non</italic>" for diagnosis.<xref ref-type="bibr" rid="article-26391.r24">[24]</xref>&#x000a0;The amount of matrix may vary from well-formed trabeculae (which point towards a benign process), dense osteoid (seen in the sclerotic variant of osteoblastic OGS) to inconspicuous amounts of the matrix (seen in fibroblastic or small cell variant of osteogenic sarcoma).<xref ref-type="bibr" rid="article-26391.r25">[25]</xref></p>
        <p>Osteoid is characterized histologically as being glassy, densely eosinophilic, and homogenous. Osteoid deposition by malignant cells may be described by the following patterns &#x02013; filigree or lacelike (delicate and anastomosing), sclerotic (dense confluent sheets of the matrix), and thick trabeculae (which may mimic dense bone).<xref ref-type="bibr" rid="article-26391.r26">[26]</xref></p>
        <p>The most common histologic subtype is the osteoblastic variant of conventional osteosarcoma, which shows a preponderance of a lacelike osteoid matrix without the presence of significant chondroid or fibrous matrix.<xref ref-type="bibr" rid="article-26391.r27">[27]</xref>&#x000a0;Epithelioid tumor cells may be seen growing in clusters surrounded by osteoid.<xref ref-type="bibr" rid="article-26391.r28">[28]</xref></p>
        <p>Parosteal osteosarcomas have&#x000a0;a stuck-on appearance. Histopathological examination&#x000a0;demonstrates a well-differentiated fibrous tissue with osseous components, hypocellular spindle cell stroma with well-differentiated trabeculae. These may undergo dedifferentiation into dedifferentiated parosteal osteosarcoma (DPOS), which may demonstrate the presence of high-grade spindle cell sarcoma along with the primary tumor.<xref ref-type="bibr" rid="article-26391.r22">[22]</xref></p>
      </sec>
      <sec id="article-26391.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>
<bold>Presenting Complaints</bold>
</p>
        <p>Pain and swelling at the local site, usually at the growing ends of an extremity (long bone), are the common presenting symptoms.<xref ref-type="bibr" rid="article-26391.r29">[29]</xref>&#x000a0;Absence of signs of infection (local signs and symptoms mimicking osteomyelitis -&#x000a0;usually considered to be more common with Ewing's sarcoma), history of antecedent trauma, or history of receiving irradiation to the site may also offer a clue to the diagnosis.<xref ref-type="bibr" rid="article-26391.r30">[30]</xref></p>
        <p>Many patients present with pathological fracture due to primary tumor or bony metastases (bone to bone spread).<xref ref-type="bibr" rid="article-26391.r31">[31]</xref>&#x000a0;Others&#x000a0;with metastasis present with symptoms pertaining to the organ, frequent cough, and hemoptysis with pulmonary metastases.<xref ref-type="bibr" rid="article-26391.r32">[32]</xref></p>
        <p>
<bold>Signs</bold>
</p>
        <p>Palpable mass, restriction of joint movement, pain on weight-bearing, localized warmth, and inflammatory erythema at the site of involvement are common signs.<xref ref-type="bibr" rid="article-26391.r4">[4]</xref></p>
        <p>Constitutional signs and symptoms may be absent until the advanced stage of the disease.<xref ref-type="bibr" rid="article-26391.r29">[29]</xref></p>
        <p>The preoperative neurological deficit in vertebral osteosarcoma can be assessed according to the Bradford and Mac bride modification of the Frankel grading system.<xref ref-type="bibr" rid="article-26391.r33">[33]</xref> The classification given by Tomita et al can be used to classify the location and grade of spinal tumors.<xref ref-type="bibr" rid="article-26391.r33">[33]</xref><xref ref-type="bibr" rid="article-26391.r34">[34]</xref></p>
      </sec>
      <sec id="article-26391.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Initial&#x000a0;investigations include the following:</p>
        <p><bold>Imaging:</bold> A&#x000a0;radiograph of the local site (in two planes) will show&#x000a0;periosteal reaction (sunburst appearance, Codman's triangle) with osteoid deposition on the radiograph.<xref ref-type="bibr" rid="article-26391.r35">[35]</xref>&#x000a0;A normal X-ray might not rule out the existence of a sarcoma conclusively, and MRI might be indicated in the event of continuing bone pain to rule out a bony pathology.<xref ref-type="bibr" rid="article-26391.r36">[36]</xref></p>
        <p>In craniofacial osteosarcomas, a radiograph may not always show the typical sunburst appearance, and may instead show radiolucent to radioopaque lesions depending upon the degree of calcification or osteoid formation.<xref ref-type="bibr" rid="article-26391.r37">[37]</xref><xref ref-type="bibr" rid="article-26391.r38">[38]</xref></p>
        <p>Areas of bony cortical destruction, microcalcifications, and periosteal bone formations may be better visualized on a Computed Tomographic scan, which may be performed in cases of diagnostic uncertainty, or when an MRI is contraindicated.<xref ref-type="bibr" rid="article-26391.r39">[39]</xref><xref ref-type="bibr" rid="article-26391.r40">[40]</xref></p>
        <p>Tc 99 whole-body bone scanning or F 18 - FDG PETmay be indicated for ruling out other sites of bone to bone metastasis, "skip lesions."<xref ref-type="bibr" rid="article-26391.r39">[39]</xref><xref ref-type="bibr" rid="article-26391.r35">[35]</xref></p>
        <p><bold>Blood tests:</bold> This includes&#x000a0;complete blood count and biochemistry, serum ALP, ESR.</p>
        <p><bold>Biopsy:</bold>&#x000a0;USG, MRI, or CT guided core needle biopsy might prove to be adequate in most cases. The histopathological specimen should be sent for molecular, genetic, microbiological studies.&#x000a0;While there is some evidence to support the assumption that not all needle tracts need to be resected, all open biopsy tracts should be resected.<xref ref-type="bibr" rid="article-26391.r41">[41]</xref></p>
        <p>The role of liquid biopsy in osteosarcoma is still in flux. However, this may be considered if the results of tissue biopsy are unconvincing. It detects&#x000a0;circulating tumor cells, circulating tumor DNA, and micro RNA.<xref ref-type="bibr" rid="article-26391.r42">[42]</xref></p>
        <p><bold>Pre chemotherapy evaluation:&#x000a0;</bold>Chemotherapy may result in auditory, renal, and cardiac toxicity, making baseline assessment of these parameters extremely important.&#x000a0;Pure tone audiometry, baseline renal function testing, and echocardiographic evaluation might be warranted.<xref ref-type="bibr" rid="article-26391.r43">[43]</xref></p>
      </sec>
      <sec id="article-26391.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Overview of the Treatment of Osteosarcoma</bold>
</p>
        <p>Multimodality therapy consisting of neoadjuvant chemotherapy, followed by surgery and chemotherapy in the adjuvant setting, is considered the treatment of choice.<xref ref-type="bibr" rid="article-26391.r44">[44]</xref><xref ref-type="bibr" rid="article-26391.r45">[45]</xref>&#x000a0;The combination of chemotherapy, surgical procedures, and advanced imaging modalities has led to an increase in limb salvage rates from 53% in the 1980s to greater than 90% in recent times.<xref ref-type="bibr" rid="article-26391.r46">[46]</xref>&#x000a0;Along&#x000a0;with an improvement in psychological and cosmetic outcomes, limb salvage procedures have comparable&#x000a0;overall survival and local recurrence rates to amputation.<xref ref-type="bibr" rid="article-26391.r9">[9]</xref>&#x000a0;The utility of neoadjuvant chemotherapy has been attributed to the presence of subclinical micrometastatic disease.<xref ref-type="bibr" rid="article-26391.r6">[6]</xref></p>
        <p>Enrollment in a clinical trial should be considered in all cases.&#x000a0;General principles of management include,</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Localized, low-grade <bold>osteosarcoma</bold></bold>
<list list-type="bullet"><list-item><p>Wide excision is the treatment of choice.</p></list-item><list-item><p>Neoadjuvant chemotherapy is usually not recommended, except when it is a periosteal lesion.</p></list-item><list-item><p>If high-grade on the surgical specimen, adjuvant chemotherapy is warranted.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Localized, high-grade osteosarcoma</bold>
<list list-type="bullet"><list-item><p>Neoadjuvant chemotherapy followed by surgery is the standard&#x000a0;of care.
<list list-type="bullet"><list-item><p>Limb sparing surgery is considered in those with a good histologic response to chemotherapy.&#x000a0;</p></list-item></list>
</p></list-item><list-item><p>Depending on margins and response to neoadjuvant chemotherapy at the time of surgery, postoperative treatment involves chemotherapy with or without local therapy&#x000a0;(radiation and/or&#x000a0;re-resection).
<list list-type="bullet"><list-item><p>Assessment of histological response to neoadjuvant treatment is of paramount importance in deciding the choice of chemotherapy.</p></list-item></list>
</p></list-item><list-item><p>If unresectable, chemoradiation is preferred.&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Metastatic&#x000a0;<bold>osteosarcomas</bold></bold>
<list list-type="bullet"><list-item><p>Neoadjuvant chemotherapy followed by wide excision of the primary tumor, along with metastasectomy, is indicated in pulmonary, visceral, or skeletal metastases if&#x000a0;deemed resectable.</p></list-item><list-item><p>Chemotherapy, with or without radiation therapy, followed by reassessment of the primary site for local control, is indicated in unresectable metastatic disease.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Relapsed or refractory osteosarcoma</bold>
<list list-type="bullet"><list-item><p>Resection or second-line chemotherapy or a combination of the two is preferred.
<list list-type="bullet"><list-item><p>Metastatectomy of bony metastases may be associated with poorer survival when compared to those who undergo resection of pulmonary only metastases.</p></list-item></list>
</p></list-item><list-item><p>If&#x000a0;disease progression is evidenced, palliative radiation or best supportive treatment can be&#x000a0;offered.<xref ref-type="bibr" rid="article-26391.r47">[47]</xref><xref ref-type="bibr" rid="article-26391.r48">[48]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Response Assessment following Neoadjuvant Chemotherapy&#x000a0;</bold>
</p>
        <p>The degree of histological necrosis has been shown to correlate with the disease-free survival in patients who have received neoadjuvant chemotherapy.<xref ref-type="bibr" rid="article-26391.r49">[49]</xref>&#x000a0;Less than &#x0003c;10%&#x000a0;of viable cells on the biopsy specimen correlates with a favorable response and an improvement in disease-free survival.</p>
        <p>Huvos was the first to describe the grade of histological necrosis in biopsy specimens from patients who had been treated with Von Rosen's protocol. These were classified from grade I to IV, with grade II and IV corresponding to complete response to therapy.<xref ref-type="bibr" rid="article-26391.r50">[50]</xref>&#x000a0;Rosen observed that those with grade III-IV responses had improved disease-free survival.<xref ref-type="bibr" rid="article-26391.r51">[51]</xref></p>
        <p>
<bold>Relapsed/Recurrent Osteosarcoma With or Without Metastasis</bold>
</p>
        <p>Treatment options include,</p>
        <list list-type="bullet">
          <list-item>
            <p>If possible, surgical resection is preferred. Mostly, adjuvant chemotherapy is given.
<list list-type="bullet"><list-item><p>A 5-year survival rate of 33% may be obtained in patients in whom a second surgical remission can be achieved.<xref ref-type="bibr" rid="article-26391.r41">[41]</xref><xref ref-type="bibr" rid="article-26391.r48">[48]</xref></p></list-item><list-item><p>Recommended chemotherapy regimens have been listed in the 'medical oncology' section.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>If not candidates for surgery,
<list list-type="bullet"><list-item><p>Chemotherapy with or without radiation is preferred.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>In those with metastasis, dismal 5-year survival rates of 20%, which has&#x000a0;remained unchanged over the past 25 years, underline the need to explore newer approaches.</p>
        <p>
<bold>Supportive Management/Palliative Medicine</bold>
</p>
        <p>The management of chemotherapy-related complications such as nausea and vomiting, anemia, neutropenic fever, fatigue, neuropathy, &#x000a0;and cardiotoxicity, provision of symptom directed therapy, and counseling regarding goals of care discussions, has shown improvement in the quality of life. Provision of continuity of care through&#x000a0;home care and round the clock telephonic liaison might assume special significance, given the existing circumstances (ongoing SARS -COV -2 pandemic). Hospice should be considered early.<xref ref-type="bibr" rid="article-26391.r52">[52]</xref><xref ref-type="bibr" rid="article-26391.r53">[53]</xref></p>
        <p>
<bold>Special Situations</bold>
</p>
        <p>Surface osteosarcomas<xref ref-type="bibr" rid="article-26391.r22">[22]</xref><xref ref-type="bibr" rid="article-26391.r21">[21]</xref></p>
        <p>Surface osteosarcomas are variants with comparatively lower malignant potential. Management is as following,</p>
        <list list-type="bullet">
          <list-item>
            <p>Curative surgery remains the treatment of choice.
<list list-type="bullet"><list-item><p>While local resection may be recommended for conventional parosteal osteosarcoma, wider margins are recommended in patients undergoing curative resections for high-grade surface osteosarcomas (dedifferentiated parosteal osteosarcomas and high-grade osteosarcomas).</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Chemotherapy is usually not recommended in the treatment of conventional parosteal osteosarcoma after a retrospective analysis failed to demonstrate any benefit in survival.
<list list-type="bullet"><list-item><p>If high-grade areas are visualized on the histopathology specimen, treatment with adjuvant chemotherapy is advised. Though the exact benefits of chemotherapy have not been earmarked, there is a consensus that standard chemotherapy regimens be used in high-grade surface osteosarcomas.</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26391.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Osteoblastic osteosarcoma can be confused with&#x000a0;an osteoblastoma or&#x000a0;a fracture callus.<xref ref-type="bibr" rid="article-26391.r26">[26]</xref></p>
        <p>While, osteoblastic osteosarcoma, originates in the meta-diaphysis of the bony appendicular skeleton, consists of sheets of atypical cells within an osteoid matrix, may demonstrate entrapment of pre-existing bone with a permeative growth pattern often with extension into the soft tissue and presence of atypical mitoses with a high rate of replicating cells, osteoblastoma is usually well-circumscribed, with a peripheral rim of reactive bone, consisting of a loose fibrous stroma with a vascular component, rimming of bone trabeculae and absence of atypical mitoses. Callus formation is usually associated with a history of accompanying trauma, organized matrix deposition, presence of granulation tissue-like stroma, presence of hyaline cartilage with woven lamellar bone, and presence of transition area from immature osteoid to that of osteoblasts lined bony spicules.</p>
        <p>While conventional skeletal chondrosarcoma and dedifferentiated chondrosarcoma are the closest differentials of chondroblastic osteosarcoma, fibrosarcoma/undifferentiated pleomorphic sarcoma and desmoplastic fibroma may mimic fibroblastic osteosarcoma. Among the list of differentials for morphologic variants, an aneurysmal bone cyst might be considered a close differential for telangiectatic osteosarcoma. At the same time, Ewing sarcoma/ primitive neuroectodermal tumor may resemble a small cell variant of osteogenic sarcoma. Fibrous dysplasia and desmoplastic fibroma mimic low-grade intraosseous osteosarcoma. Giant cell-rich osteosarcoma needs to be differentiated from a giant cell tumor of the bone (osteoclastoma).</p>
        <p>Among surface osteosarcomas, low-grade parosteal osteosarcoma needs to be differentiated from osteochondroma, heterotropic ossification, and surface osteoma. Chondroblastic osteosarcoma and periosteal chondrosarcoma form the closest differentials for periosteal osteosarcoma (intermediate grade surface osteosarcoma), while reactive surface lesions need to be considered in the differential of high-grade surface osteosarcoma.</p>
      </sec>
      <sec id="article-26391.s11" sec-type="Surgical Oncology">
        <title>Surgical Oncology</title>
        <p>
<bold>Surgery&#x000a0;</bold>
<xref ref-type="bibr" rid="article-26391.r41">[41]</xref>
<xref ref-type="bibr" rid="article-26391.r48">[48]</xref>
<xref ref-type="bibr" rid="article-26391.r54">[54]</xref>
<xref ref-type="bibr" rid="article-26391.r55">[55]</xref>
</p>
        <p>Surgical resection is the treatment modality of choice. Limb salvage surgery has grown in importance over the past few decades. The goals of surgery are manifold, primarily removal of the tumor with&#x000a0;clear microscopic margins in addition to the preservation of the functional status.</p>
        <p>The definition of a clear margin needs to be interpreted in the context of certain developments which have allowed better scrutiny of the survival &#x02013; tumors that are localized to only a part of the bone may be cleared in an intercalated fashion, avoiding resection at the articular surface and normal bone in order to obtain a better functional outcome. The choice of the operative procedure may be changed from a salvage surgery to a rotationplasty or amputation in those with a poor response to neoadjuvant chemotherapy. A wider margin of uninvolved fat would be preferred to the fascia, as the tumor is more likely to invade fat than bone.</p>
        <p>A higher risk of local recurrence has come to be associated with local salvage when compared to amputation. However, this has not been shown to correlate with poorer overall survival.</p>
        <p>Amputation may be preferred in cases where the achievement of disease-free margins will lead&#x000a0;to a non-functional limb or when the patient preference is for a bioprosthesis with the potential to provide a greater degree of functionality (over the cosmetic advantages that might accompany a limb salvage.</p>
        <p>Rotationplasty, which involves an intercalary resection of the bone followed by rotation up to 180 degrees craniocaudally with the rotated ankle serving as the knee joint, has the potential to provide excellent oncological, functional, and psychological outcomes.</p>
        <p>Compressive osteointegration, allograft bone reconstruction, and a hybrid approach that utilizes side plates in developing an augmented cemented intramedullary fixation constitute advances with the potential to improve post-surgical rehabilitation and quality of life.</p>
        <p>Local ablative therapies such as stereotactic radiosurgery, cryotherapy, or radiofrequency may be indicated in the management of solitary pulmonary metastasis.<xref ref-type="bibr" rid="article-26391.r56">[56]</xref><xref ref-type="bibr" rid="article-26391.r57">[57]</xref><xref ref-type="bibr" rid="article-26391.r58">[58]</xref><xref ref-type="bibr" rid="article-26391.r59">[59]</xref><xref ref-type="bibr" rid="article-26391.r5">[5]</xref></p>
      </sec>
      <sec id="article-26391.s12" sec-type="Radiation Oncology">
        <title>Radiation Oncology</title>
        <p>
<bold>Radiotherapy&#x000a0;</bold>
<xref ref-type="bibr" rid="article-26391.r41">[41]</xref>
<xref ref-type="bibr" rid="article-26391.r60">[60]</xref>
<xref ref-type="bibr" rid="article-26391.r61">[61]</xref>
<xref ref-type="bibr" rid="article-26391.r62">[62]</xref>
<xref ref-type="bibr" rid="article-26391.r48">[48]</xref>
</p>
        <p>Radiation therapy is indicated in the management of tumors that are deemed inoperable at initial presentation, pulmonary metastases that have been proven to be resistant to chemotherapy, and palliation of spinal cord compression and bone pain.</p>
        <p>Radiotherapy may have a role in whom complete surgical resection cannot be achieved due to the anatomical location (pelvis, vertebrae, and the base of the skull) involved or in case of patient refusal for undergoing surgery. The multimodality treatment in such cases involves chemotherapy in addition to high dose photon radiotherapy (50-70 Gray). RT may have a role in such cases and may lead to an increase in the progression-free interval.</p>
        <p>RT&#x000a0;has also been postulated to have a role in the management of low-grade parosteal osteosarcomas when surgery is not deemed to be feasible, although this needs to be subjected to further scrutiny through&#x000a0;clinical trials. Hypofractionation and accelerated radiotherapy are two approaches that have been used to overcome radioresistance.</p>
        <p>Newer RT techniques such as Proton beam radiotherapy and carbon ion beam radiotherapy should be considered in the treatment of primary unresectable tumors. Intraoperative extracorporeal irradiation, which involves primary tumor resection with limb salvage involving the removal of the affected bony segment and subjecting it to a single dose of extracorporeal irradiation (50 Gray), before re-implanting it, has shown favorable results and needs to be evaluated further.</p>
      </sec>
      <sec id="article-26391.s13" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>
<bold>European and American Osteosarcoma Study (EURAMOS)&#x000a0;</bold>
<xref ref-type="bibr" rid="article-26391.r63">[63]</xref>
<xref ref-type="bibr" rid="article-26391.r64">[64]</xref>
<xref ref-type="bibr" rid="article-26391.r63">[63]</xref>
</p>
        <p>The European and American osteosarcoma study is a collaborative trial with the involvement of four study groups, who have come together with an aim to improve treatment outcomes in the study population.&#x000a0;Patients aged less than 40 years, with or without metastasis and high-grade osteosarcoma, were enrolled in this trial and received standard chemotherapy in the form of methotrexate, doxorubicin, and cisplatin in the adjuvant setting. Good response to treatment was defined as the presence of viable tumor less than 10%.</p>
        <p>The addition of pegylated interferon-alpha 2 b, in addition to standard chemotherapy in the good response group, was studied. The addition of pegylated interferon-alpha 2 b did not affect the disease-free survival or the overall survival.</p>
        <p>Ifosfamide and etoposide (IE) were used in addition to the standard chemotherapy protocol in those with a poor histological response to neoadjuvant chemotherapy at resection. The addition of IE failed to demonstrate an improvement in DFS or OS. Standard therapy with the MAC regimen has been advised as the chemotherapeutic regimen of choice in high-grade osteosarcoma.</p>
        <p>
<bold>INTERGROUP 0133 Study&#x000a0;</bold>
<xref ref-type="bibr" rid="article-26391.r65">[65]</xref>
<xref ref-type="bibr" rid="article-26391.r66">[66]</xref>
</p>
        <p>The Intergroup 0133 study is a phase III&#x000a0;randomized control trial with a two by two factorial study design, which was designed to study the effect of the addition of ifosfamide to the existing standardized chemotherapy, and assess whether the addition of mifamurtide&#x000a0;had any impact on the survival in patients with newly diagnosed osteosarcoma. The addition of ifosfamide to the standard regimen did not lead to an improvement in EFS. The study showed that the addition of mifamurtide improved overall survival, but there was no change in EFS when added to standard chemotherapy. However, this&#x000a0;difference is OS was later noted to be&#x000a0;statistically insignificant.</p>
      </sec>
      <sec id="article-26391.s14" sec-type="Medical Oncology">
        <title>Medical Oncology</title>
        <p>
<bold>Chemotherapy for Osteosarcoma </bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Chemotherapy is the standard of care. It can be given either neoadjuvant and/or adjuvant setting.&#x000a0;The ideal&#x000a0;timing of chemotherapy (i.e., preoperative versus postoperative) is not clear. 
<list list-type="bullet"><list-item><p>Von Rosen was the first to introduce the concept of neoadjuvant chemotherapy in the management of osteosarcoma.<xref ref-type="bibr" rid="article-26391.r9">[9]</xref><xref ref-type="bibr" rid="article-26391.r67">[67]</xref>&#x000a0;The objective was to provide ample time for the development of customized prostheses and reduction in the tumor load.
<list list-type="bullet"><list-item><p>Besides, the advantages of neoadjuvant chemotherapy&#x000a0;include an improvement in the quality of life brought about the amelioration of symptoms, treatment of micrometastatic disease, to increase chances of complete resection, and assessment of response to chemotherapy (degree of necrosis).<xref ref-type="bibr" rid="article-26391.r68">[68]</xref><xref ref-type="bibr" rid="article-26391.r69">[69]</xref>&#x000a0;The extent of the response to neoadjuvant chemotherapy has been used to predict survival.<xref ref-type="bibr" rid="article-26391.r70">[70]</xref>&#x000a0;Neoadjuvant chemotherapy has increased the proportion of patients qualifying for&#x000a0;limb-salvage surgery; however, chemotherapy should not be considered a substitute for adequate surgery.</p></list-item></list>
</p></list-item><list-item><p>In those who receive neoadjuvant chemotherapy, if the tumor at the surgery has &#x02265;&#x000a0;10% residual cancer, a change in the chemotherapeutic regimen might be beneficial (MD Anderson approach).<xref ref-type="bibr" rid="article-26391.r71">[71]</xref>&#x000a0;Although this is a debatable&#x000a0;area.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Regimens for nonmetastatic, resectable disease:</bold>
<list list-type="bullet"><list-item><p>The standard of care is
<list list-type="bullet"><list-item><p>Cisplatin and doxorubicin,</p></list-item><list-item><p>MAP (high-dose methotrexate (HD-MTX), doxorubicin, and cisplatin), or</p></list-item><list-item><p>MAP + Ifosfamide per the AOST 0331 (EURAMOS-1) trial<xref ref-type="bibr" rid="article-26391.r63">[63]</xref><xref ref-type="bibr" rid="article-26391.r67">[67]</xref>
<list list-type="bullet"><list-item><p>Three and four-drug combinations are preferred for young patients (&#x0003c;40 years old), with good performance status</p></list-item><list-item><p>10 weeks of neoadjuvant chemotherapy</p></list-item><list-item><p>19 weeks of adjuvant chemotherapy (starting one week postoperatively)</p></list-item><list-item><p>Caution should be exercised with high-dose methotrexate in adults.&#x000a0;</p></list-item></list>
</p></list-item></list>
</p></list-item><list-item><p>For those intolerant to HD-MTX,&#x000a0;
<list list-type="bullet"><list-item><p>Carboplatin, ifosfamide, and doxorubicin is a reasonable approach. However, this has a higher risk of secondary malignancies.</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Regimens for relapsed/refractory disease:</bold>
<list list-type="bullet"><list-item><p>Etoposide plus ifosfamide is the most commonly used second-line regimen.</p></list-item><list-item><p>Other options include<xref ref-type="bibr" rid="article-26391.r47">[47]</xref><xref ref-type="bibr" rid="article-26391.r72">[72]</xref><xref ref-type="bibr" rid="article-26391.r73">[73]</xref><xref ref-type="bibr" rid="article-26391.r48">[48]</xref><xref ref-type="bibr" rid="article-26391.r74">[74]</xref><xref ref-type="bibr" rid="article-26391.r75">[75]</xref><xref ref-type="bibr" rid="article-26391.r76">[76]</xref>
<list list-type="bullet"><list-item><p>regorafenib,</p></list-item><list-item><p>high dose ifosfamide &#x000b1;&#x000a0;etoposide,</p></list-item><list-item><p>sorafenib (alone or in combination with everolimus),</p></list-item><list-item><p>cyclophosphamide and topotecan,</p></list-item><list-item><p>docetaxel&#x000a0;and gemcitabine, or</p></list-item><list-item><p>gemcitabine alone.</p></list-item></list>
</p></list-item><list-item><p>The following combinatorial regimens may be considered useful in specific circumstances - cyclophosphamide and etoposide; ifosfamide, carboplatin, and etoposide; HD-MTX, etoposide, and ifosfamide.<xref ref-type="bibr" rid="article-26391.r48">[48]</xref><xref ref-type="bibr" rid="article-26391.r77">[77]</xref><xref ref-type="bibr" rid="article-26391.r73">[73]</xref></p></list-item><list-item><p>Samarium 153 &#x02013; ethylene diamine tetramethylene diphosphonate is indicated in the management of relapsed or refractory disease after progression on second-line therapy.<xref ref-type="bibr" rid="article-26391.r78">[78]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Regimens for metastatic disease at diagnosis:</bold>&#x000a0;
<list list-type="bullet"><list-item><p>If not a candidate for surgery, there is no consensus. Common options include
<list list-type="bullet"><list-item><p>AOST 0331 protocol (HDMTX, doxorubicin, and cisplatin), or</p></list-item><list-item><p>AOST 06P1 protocol (HDMTX plus doxorubicin, cisplatin, ifosfamide, and etoposide)</p></list-item></list>
</p></list-item><list-item><p>Other treatment approaches that have been evaluated in the metastatic setting -&#x000a0;concomitant use of HD-MTX&#x000a0;and ifosfamide; etoposide and ifosfamide in the maximum tolerated doses along with the use of haematopoetic stem cell factors;&#x000a0;carboplatin and etoposide; gemcitabine and docetaxel, and use of liposomal and aerosolized preparations.<xref ref-type="bibr" rid="article-26391.r79">[79]</xref><xref ref-type="bibr" rid="article-26391.r41">[41]</xref><xref ref-type="bibr" rid="article-26391.r48">[48]</xref><xref ref-type="bibr" rid="article-26391.r80">[80]</xref><xref ref-type="bibr" rid="article-26391.r48">[48]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Radiopharmaceuticals</bold>
</p>
        <p>Intratumoral heterogeneity limits the use of radiopharmaceuticals such as 153-Sm-EDTMP and 153-Sm-DOTA. Radium 223, in combination with chemotherapeutic approaches, may be used.<xref ref-type="bibr" rid="article-26391.r81">[81]</xref>&#x000a0;Combinatorial approaches are being evaluated in ongoing trials (NCT 03478462)</p>
        <p>
<bold>Immunotherapy</bold>
</p>
        <p>A higher percentage of CD 8 positive T lymphocytes within the tumor has&#x000a0;been shown to correlate positively with the prognosis. A higher degree of genomic instability and PD-L1 expression also point towards the possibility of heightened sensitivity to immune checkpoint blockade. Multiple cell-surface proteins have also been exploited as possible targets of treatment.&#x000a0;</p>
        <p>Three specific approaches involving targeted antibodies have been suggested &#x02013; monoclonal antibodies targeting cell surface proteins, bispecific T cell engagers, and antibodies coupled cytotoxic agents.<xref ref-type="bibr" rid="article-26391.r82">[82]</xref></p>
        <p>Monoclonal antibodies that have been explored for exploring a potentially beneficial role include trastuzumab against HER 2, cixutumumab, which targets insulin-like growth factor 1, and the monoclonal antibody against glycoprotein nonmetastatic B - glembatumumab vedotin. Monoclonal antibodies targeting disialoganglioside GM 2 (found in both primary and recurrent tumors) alone or in combination with other immunoadjuvants such as sargramostim or interleukin two have also been used.</p>
        <p>Other immunotherapy approaches include dendritic cell vaccines in combination&#x000a0;with chemotherapeutic agents such as decitabine (to upregulate antigen expression) and gemcitabine (to increase cytotoxicity directed against tumor cells and decrease myeloid stem cells). A trial combining the first viral oncolytic therapy T-Vec (Talimogene laherparepvec) along with PD 1 blockade in the management of sarcomas is underway.</p>
        <p>While Chimeric antigen receptor T cells Insulin-like growth factor 1 receptor and tyrosine kinase-like orphan receptor one have demonstrated prolongation of survival in preclinical studies, CART cells targeting HER-2 are being studied in the adult osteosarcoma population. Future adoptive therapies involving the use of gamma delta T cells, unmodified CD 8 T cells, and T cells engineered with high-affinity receptors are in the pipeline. &#x000a0;A pediatric phase II&#x000a0;trial of ipilimumab in the pediatric age group demonstrated a similar toxicity profile along with an increase in activated CD 8 lymphocytes. The absence of absolute anti-tumor responses has not deterred the exploration of various combination immunotherapy approaches directed against CTLA &#x02013; 4, PD -1, and PD &#x02013; L1. &#x000a0;&#x000a0;</p>
        <p>Strategies that target the tumor microenvironment have also been developed for use in the clinical trial setting.</p>
        <p><bold>Bone Targeted Therapies</bold>&#x000a0;</p>
        <p>Osteosarcomas are unique in that bone-targeted therapies such as bisphosphonates and anti RANK ligand monoclonal antibody (denosumab) have been evaluated in trials, which were aimed at re-positioning these approaches, which are otherwise&#x000a0;supportive, as curative. &#x000a0;The use of bisphosphonates in osteosarcomas is only recommended in the setting of a clinical trial after a recent study evaluating the role of zoledronic acid in combination with chemotherapy failed to demonstrate an improvement in the overall survival, relapse-free survival, or the histological response.<xref ref-type="bibr" rid="article-26391.r83">[83]</xref><xref ref-type="bibr" rid="article-26391.r84">[84]</xref></p>
      </sec>
      <sec id="article-26391.s15" sec-type="Staging">
        <title>Staging</title>
        <p>The two staging systems used in the classification of osteosarcomas include</p>
        <list list-type="bullet">
          <list-item>
            <p>Enneking system, and</p>
          </list-item>
          <list-item>
            <p>TNM system - proposed by the American Joint Committee of Cancer&#x000a0;(AJCC)/International Union against Cancer.</p>
          </list-item>
        </list>
        <p>While the TNM staging is based upon the size, nodal involvement, and metastatic extent of the tumor, the Enneking system uses the histological grade and extent in relation to the histological compartment. The histological grade is divided into low and high grade. The anatomical compartmentalization of the tumor may be intra-compartmental or extra-compartmental.<xref ref-type="bibr" rid="article-26391.r41">[41]</xref><xref ref-type="bibr" rid="article-26391.r48">[48]</xref></p>
      </sec>
      <sec id="article-26391.s16" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Prior to the advent of chemotherapy, the 5-year overall survival rate was between 10% to 20% only<xref ref-type="bibr" rid="article-26391.r46">[46]</xref>. While the five-year survival of localized extremity osteosarcomas approaches 70%, pelvic osteosarcomas have a relatively poorer prognosis with a five-year survival of 30%.<xref ref-type="bibr" rid="article-26391.r17">[17]</xref>&#x000a0;The failure to obtain a positive margin (intralesional resections), lack of response to neoadjuvant chemotherapy (denoted by the poorer percentage of necrosis), and pathological fracture&#x000a0;are associated with a poor prognosis (with higher rates of local recurrence).<xref ref-type="bibr" rid="article-26391.r85">[85]</xref></p>
        <p>The presence of metastatic disease at presentation has the worst impact on prognosis, with overall survival ranging between 20 to 30%.<xref ref-type="bibr" rid="article-26391.r86">[86]</xref>&#x000a0;Bone metastases and non-pulmonary metastases&#x000a0;fare poorer than those with only pulmonary involvement.<xref ref-type="bibr" rid="article-26391.r87">[87]</xref></p>
        <p>Male sex, non-caucasian race, elevated&#x000a0;ALP, and LDH levels have also been associated with a poor prognosis.<xref ref-type="bibr" rid="article-26391.r88">[88]</xref>&#x000a0;Osteosarcomas arising in diseased bones such as those with Paget&#x02019;s disease and irradiated bone have also been shown to be associated with a poorer prognosis.<xref ref-type="bibr" rid="article-26391.r89">[89]</xref><xref ref-type="bibr" rid="article-26391.r90">[90]</xref></p>
        <p>The histological subtype of the tumor, which may also prove to be crucial in determining the response to treatment may also be a determinant of prognosis.<xref ref-type="bibr" rid="article-26391.r26">[26]</xref>&#x000a0;It has been shown that telangiectatic and fibroblastic tumors have a better prognosis (and a better response to chemotherapy) as compared to chondroblastic and osteoblastic subtypes.<xref ref-type="bibr" rid="article-26391.r26">[26]</xref></p>
        <p>Craniofacial osteosarcomas are usually low-grade tumors and have been considered to have a favorable prognosis when compared to extremity osteosarcomas.<xref ref-type="bibr" rid="article-26391.r91">[91]</xref>&#x000a0;Radiotherapy related craniofacial osteosarcomas are generally considered to be more aggressive than primary craniofacial osteosarcomas.<xref ref-type="bibr" rid="article-26391.r92">[92]</xref></p>
        <p>Naples prognostic score that includes four parameters namely serum albumin level, serum cholesterol, neutrophil to lymphocyte ratio, and monocyte to lymphocyte ratio, has also been proposed for preoperative prognostication and has been shown to correlate with Enneking stage, presence of pathological fracture, local recurrence, and presence of metastasis.<xref ref-type="bibr" rid="article-26391.r93">[93]</xref>&#x000a0;A preoperative prognostic model that uses ESR and CRP has also been proposed.<xref ref-type="bibr" rid="article-26391.r94">[94]</xref></p>
      </sec>
      <sec id="article-26391.s17" sec-type="Complications">
        <title>Complications</title>
        <p>
<bold>Pathological Fracture&#x000a0;</bold>
<xref ref-type="bibr" rid="article-26391.r95">[95]</xref>
<xref ref-type="bibr" rid="article-26391.r96">[96]</xref>
<xref ref-type="bibr" rid="article-26391.r97">[97]</xref>
<xref ref-type="bibr" rid="article-26391.r98">[98]</xref>
<xref ref-type="bibr" rid="article-26391.r99">[99]</xref>
</p>
        <p>Treatment may include a conservative or surgical approach. Structurally significant bone destruction, a sudden change in character and intensity of pain, presence of incident pain, uncertainty about the degree of destruction, presence of solitary bone metastasis to exclude a different primary tumor are considered indications which should invite a discussion at a site-specific interdisciplinary disease management group.</p>
        <p>Referral to an orthopedic surgeon is indicated when&#x000a0;prophylactic fixation is&#x000a0;indicated, risk of impending pathological fracture is high (Mirel's score greater than equal to 8 or presence of features which have been included in Harrington's classic criteria), reconstruction or stabilization following a pathological fracture or stabilization of spinal cord instability (in vertebral fractures/metastatic spinal cord compression) is required.</p>
        <p>The following criteria have been included in the Harrington's criteria to determine the risk of a pathological fracture in the proximal femur,</p>
        <list list-type="bullet">
          <list-item>
            <p>Destruction of 50% of the circumference of the cortical bone,</p>
          </list-item>
          <list-item>
            <p>persistent pain on weight-bearing despite appropriate local irradiation,</p>
          </list-item>
          <list-item>
            <p>proximal femoral lesions in excess of 2.5 cm in size, and</p>
          </list-item>
          <list-item>
            <p>proximal femoral lesions with avulsion of the greater trochanter.&#x000a0;</p>
          </list-item>
        </list>
        <p>An interventional radiology review for radiofrequency ablation of metastatic bone disease may be indicated. Percutaneous kyphoplasty and cement vertebroplasty are minimally invasive approaches that may be indicated in cases of painful vertebral fractures.</p>
        <p>
<bold>Secondary Malignancies</bold>
</p>
        <p>The development of secondary malignant neoplasms has been seen to have increased in incidence, by a factor of 2.5% to 4% in those who receive chemotherapy. While, haematolymphoid malignancies are the most commonly observed secondary neoplasms, breast cancer, thyroid cancer, soft tissue tumors have also been observed to occur with an increased incidence in this patient population.<xref ref-type="bibr" rid="article-26391.r100">[100]</xref><xref ref-type="bibr" rid="article-26391.r101">[101]</xref></p>
      </sec>
      <sec id="article-26391.s18" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>
<bold>Areas for Future Research</bold>
<xref ref-type="bibr" rid="article-26391.r102">[102]</xref>
<xref ref-type="bibr" rid="article-26391.r103">[103]</xref>
</p>
        <p>Reasons behind the preferential spread of osteosarcoma to the bone, as well as the mechanisms underlying manipulation of the tumor stroma, need to be studied further. The mechanism underlying intertumoral and intratumoral heterogeneity also needs to be evaluated, with an emphasis on identifying actionable targets. While multiple studies are in the process of evaluating the role of receptor tyrosine kinase inhibitors, their role in combination with other strategies needs to be evaluated further.</p>
        <p>Improved modes of delivery of chemotherapy, such as aerosolized cisplatin, are also being evaluated for the management of pulmonary metastases.</p>
        <p>Novel formulations such as liposomal, lipoproteins, and microspheres may be especially effective in overcoming drug resistance and ameliorating the toxic effects of high-dose chemotherapy on local tissues. A combination of chemotherapy with stem cell therapies is also a potential future area of study.</p>
      </sec>
      <sec id="article-26391.s19" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>While the 5-year survival was close to 20% in the early 1970s, it has increased to 67% with the advent of combination chemotherapy and limb-salvage surgery.<xref ref-type="bibr" rid="article-26391.r104">[104]</xref>&#x000a0;NCCN recommends enrollment in a clinical trial, when available. Discussion in a multidisciplinary disease management group with expertise in sarcoma should be initiated as soon as the diagnosis has been made.<xref ref-type="bibr" rid="article-26391.r105">[105]</xref>&#x000a0;</p>
        <p>Discussion about the chosen modality of surgery should involve a core multidisciplinary team consisting of specialists from medical&#x000a0;oncology, surgical oncology, radiation oncology, radiology. interventional radiology and nursing.<xref ref-type="bibr" rid="article-26391.r106">[106]</xref>&#x000a0;Specialists from nuclear medicine, oncology pharmacy, psychology, and palliative medicine form a part of the extended multidisciplinary team.</p>
        <p>The tumor board discussion might involve a recapitulation of certain important points that might prove to be invaluable in deciding the type of resection &#x02013; Tumor size and extent of involvement of adjacent tissues, response to neoadjuvant therapies, and personal preferences of the patient and their family members.&#x000a0;There should be an emphasis on the challenges that are expected to follow reconstruction strategies following curative resection involving growing bones.<xref ref-type="bibr" rid="article-26391.r41">[41]</xref>&#x000a0;</p>
        <p>Effective symptom directed treatment, efficient communication, good end of life care, discontinuation of life-sustaining treatment in the event of physiological futility, and provision of palliative sedation for refractory symptoms are seminal interventions to be considered within the purview of specialist palliative medicine.</p>
      </sec>
      <sec id="article-26391.s20">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26391&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26391">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/osteogenic-sarcoma-osteosarcoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=26391">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/26391/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=26391">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-26391.s21">
        <title>References</title>
        <ref id="article-26391.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ottaviani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>The epidemiology of osteosarcoma.</article-title>
            <source>Cancer Treat Res</source>
            <year>2009</year>
            <volume>152</volume>
            <fpage>3</fpage>
            <page-range>3-13</page-range>
            <pub-id pub-id-type="pmid">20213383</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mirabello</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Troisi</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Savage</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program.</article-title>
            <source>Cancer</source>
            <year>2009</year>
            <month>Apr</month>
            <day>01</day>
            <volume>115</volume>
            <issue>7</issue>
            <fpage>1531</fpage>
            <page-range>1531-43</page-range>
            <pub-id pub-id-type="pmid">19197972</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ratnagiri</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Chaturvedi</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Extra osseous osteosarcoma of the retroperitoneum: an unusual entity.</article-title>
            <source>J Cancer Res Ther</source>
            <year>2012</year>
            <season>Jul-Sep</season>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>424</fpage>
            <page-range>424-6</page-range>
            <pub-id pub-id-type="pmid">23174726</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Durfee</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Mohammed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Luu</surname>
                <given-names>HH</given-names>
              </name>
            </person-group>
            <article-title>Review of Osteosarcoma and Current Management.</article-title>
            <source>Rheumatol Ther</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>3</volume>
            <issue>2</issue>
            <fpage>221</fpage>
            <page-range>221-243</page-range>
            <pub-id pub-id-type="pmid">27761754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tiwari</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Current concepts in surgical treatment of osteosarcoma.</article-title>
            <source>J Clin Orthop Trauma</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>4</fpage>
            <page-range>4-9</page-range>
            <pub-id pub-id-type="pmid">25983449</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taran</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Taran</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Malipatil</surname>
                <given-names>NB</given-names>
              </name>
            </person-group>
            <article-title>Pediatric Osteosarcoma: An Updated Review.</article-title>
            <source>Indian J Med Paediatr Oncol</source>
            <year>2017</year>
            <season>Jan-Mar</season>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>33</fpage>
            <page-range>33-43</page-range>
            <pub-id pub-id-type="pmid">28469335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nie</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Osteosarcoma in patients below 25 years of age: An observational study of incidence, metastasis, treatment and outcomes.</article-title>
            <source>Oncol Lett</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>16</volume>
            <issue>5</issue>
            <fpage>6502</fpage>
            <page-range>6502-6514</page-range>
            <pub-id pub-id-type="pmid">30405789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Jewell</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Gingold</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>DF</given-names>
              </name>
            </person-group>
            <article-title>Osteosarcoma: Molecular Pathogenesis and iPSC Modeling.</article-title>
            <source>Trends Mol Med</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>23</volume>
            <issue>8</issue>
            <fpage>737</fpage>
            <page-range>737-755</page-range>
            <pub-id pub-id-type="pmid">28735817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lamplot</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Denduluri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pratt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shui</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Nan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>ZL</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Haydon</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Luu</surname>
                <given-names>HH</given-names>
              </name>
            </person-group>
            <article-title>The Current and Future Therapies for Human Osteosarcoma.</article-title>
            <source>Curr Cancer Ther Rev</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>55</fpage>
            <page-range>55-77</page-range>
            <pub-id pub-id-type="pmid">26834515</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Ras-Association Domain Family 1 Isoform A (RASSF1A) Gene Polymorphism rs1989839 is Associated with Risk and Metastatic Potential of Osteosarcoma in Young Chinese Individuals: A Multi-Center, Case-Control Study.</article-title>
            <source>Med Sci Monit</source>
            <year>2016</year>
            <month>Nov</month>
            <day>23</day>
            <volume>22</volume>
            <fpage>4529</fpage>
            <page-range>4529-4535</page-range>
            <pub-id pub-id-type="pmid">27880743</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perry</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kiezun</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tonzi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Van Allen</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Baca</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Cowley</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Rheinbay</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pedamallu</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Helman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Taylor-Weiner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McKenna</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>DeLuca</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Lawrence</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Ambrogio</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sougnez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sivachenko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Walensky</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Wagle</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mora</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de Torres</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lavarino</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dos Santos Aguiar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yunes</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Brandalise</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Mercado-Celis</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Melendez-Zajgla</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>C&#x000e1;rdenas-Card&#x000f3;s</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Velasco-Hidalgo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Garraway</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Rodriguez-Galindo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gabriel</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Lander</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Golub</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Orkin</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Getz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Janeway</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2014</year>
            <month>Dec</month>
            <day>23</day>
            <volume>111</volume>
            <issue>51</issue>
            <fpage>E5564</fpage>
            <page-range>E5564-73</page-range>
            <pub-id pub-id-type="pmid">25512523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Azevedo</surname>
                <given-names>JWV</given-names>
              </name>
              <name>
                <surname>de Medeiros Fernandes</surname>
                <given-names>TAA</given-names>
              </name>
              <name>
                <surname>Fernandes</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>de Azevedo</surname>
                <given-names>JCV</given-names>
              </name>
              <name>
                <surname>Lanza</surname>
                <given-names>DCF</given-names>
              </name>
              <name>
                <surname>Bezerra</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Andrade</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>de Ara&#x000fa;jo</surname>
                <given-names>JMG</given-names>
              </name>
              <name>
                <surname>Fernandes</surname>
                <given-names>JV</given-names>
              </name>
            </person-group>
            <article-title>Biology and pathogenesis of human osteosarcoma.</article-title>
            <source>Oncol Lett</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>1099</fpage>
            <page-range>1099-1116</page-range>
            <pub-id pub-id-type="pmid">31966039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yao</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kamar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Hedgehog signalling in the tumourigenesis and metastasis of osteosarcoma, and its potential value in the clinical therapy of osteosarcoma.</article-title>
            <source>Cell Death Dis</source>
            <year>2018</year>
            <month>Jun</month>
            <day>13</day>
            <volume>9</volume>
            <issue>6</issue>
            <fpage>701</fpage>
            <pub-id pub-id-type="pmid">29899399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morrow</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Osteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate Therapies.</article-title>
            <source>Crit Rev Oncog</source>
            <year>2015</year>
            <volume>20</volume>
            <issue>3-4</issue>
            <fpage>173</fpage>
            <page-range>173-97</page-range>
            <pub-id pub-id-type="pmid">26349415</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tavanti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sero</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Vella</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fanelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Michelacci</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Landuzzi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Magagnoli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Versteeg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Picci</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hattinger</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Serra</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma.</article-title>
            <source>Br J Cancer</source>
            <year>2013</year>
            <month>Nov</month>
            <day>12</day>
            <volume>109</volume>
            <issue>10</issue>
            <fpage>2607</fpage>
            <page-range>2607-18</page-range>
            <pub-id pub-id-type="pmid">24129234</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Puranik</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Puranik</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Ramdurg</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Choudhary</surname>
                <given-names>GR</given-names>
              </name>
            </person-group>
            <article-title>Parosteal osteosarcoma: Report of a rare juxtacortical variant of osteosarcoma affecting the maxilla.</article-title>
            <source>J Oral Maxillofac Pathol</source>
            <year>2014</year>
            <season>Sep-Dec</season>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>432</fpage>
            <page-range>432-6</page-range>
            <pub-id pub-id-type="pmid">25949002</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fuchs</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hoekzema</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Inwards</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Sim</surname>
                <given-names>FH</given-names>
              </name>
            </person-group>
            <article-title>Osteosarcoma of the pelvis: outcome analysis of surgical treatment.</article-title>
            <source>Clin Orthop Relat Res</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>467</volume>
            <issue>2</issue>
            <fpage>510</fpage>
            <page-range>510-8</page-range>
            <pub-id pub-id-type="pmid">18855090</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katonis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Datsis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Karantanas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kampouroglou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lianoudakis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Licoudis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Papoutsopoulou</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Alpantaki</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Spinal osteosarcoma.</article-title>
            <source>Clin Med Insights Oncol</source>
            <year>2013</year>
            <month>Aug</month>
            <day>18</day>
            <volume>7</volume>
            <fpage>199</fpage>
            <page-range>199-208</page-range>
            <pub-id pub-id-type="pmid">24179411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chaudhary</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chaudhary</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Osteosarcoma of jaws.</article-title>
            <source>J Oral Maxillofac Pathol</source>
            <year>2012</year>
            <month>May</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>233</fpage>
            <page-range>233-8</page-range>
            <pub-id pub-id-type="pmid">22923896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cutilli</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Scarsella</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fabio</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Oliva</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cargini</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>High-grade chondroblastic and fibroblastic osteosarcoma of the upper jaw.</article-title>
            <source>Ann Maxillofac Surg</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>1</volume>
            <issue>2</issue>
            <fpage>176</fpage>
            <page-range>176-80</page-range>
            <pub-id pub-id-type="pmid">23482406</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nouri</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ben Maitigue</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Abid</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nouri</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Abdelkader</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bouaziz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mestiri</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Surface osteosarcoma: Clinical features and therapeutic implications.</article-title>
            <source>J Bone Oncol</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>115</fpage>
            <page-range>115-23</page-range>
            <pub-id pub-id-type="pmid">26730360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumar</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>Barwar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Surface osteosarcomas: Diagnosis, treatment and outcome.</article-title>
            <source>Indian J Orthop</source>
            <year>2014</year>
            <month>May</month>
            <volume>48</volume>
            <issue>3</issue>
            <fpage>255</fpage>
            <page-range>255-61</page-range>
            <pub-id pub-id-type="pmid">24932030</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Piperdi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Dorfman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tripathi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sowers</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rosenblum</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Geller</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hoang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gill</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gorlick</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Genetically transforming human osteoblasts to sarcoma: development of an osteosarcoma model.</article-title>
            <source>Genes Cancer</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>8</volume>
            <issue>1-2</issue>
            <fpage>484</fpage>
            <page-range>484-494</page-range>
            <pub-id pub-id-type="pmid">28435520</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hameed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mandelker</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Tumor Syndromes Predisposing to Osteosarcoma.</article-title>
            <source>Adv Anat Pathol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>217</fpage>
            <page-range>217-222</page-range>
            <pub-id pub-id-type="pmid">29668499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sarkar</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Pathological and clinical features of primary osseous tumours of the jaw.</article-title>
            <source>J Bone Oncol</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>3</volume>
            <issue>3-4</issue>
            <fpage>90</fpage>
            <page-range>90-5</page-range>
            <pub-id pub-id-type="pmid">26909304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonzalez</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Cates</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Osteosarcoma: Differential Diagnostic Considerations.</article-title>
            <source>Surg Pathol Clin</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>117</fpage>
            <page-range>117-46</page-range>
            <pub-id pub-id-type="pmid">26837918</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klein</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Siegal</surname>
                <given-names>GP</given-names>
              </name>
            </person-group>
            <article-title>Osteosarcoma: anatomic and histologic variants.</article-title>
            <source>Am J Clin Pathol</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>125</volume>
            <issue>4</issue>
            <fpage>555</fpage>
            <page-range>555-81</page-range>
            <pub-id pub-id-type="pmid">16627266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kashikar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Steinle</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reich</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Freedman</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Epithelioid Multinodular Osteoblastoma of the Mandible: A Case Report and Review of Literature.</article-title>
            <source>Head Neck Pathol</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>182</fpage>
            <page-range>182-7</page-range>
            <pub-id pub-id-type="pmid">26507845</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stitzlein</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Wojcik</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sebro</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Balamuth</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Team Approach: Osteosarcoma of the Distal Part of the Femur in Adolescents.</article-title>
            <source>JBJS Rev</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>5</volume>
            <issue>12</issue>
            <fpage>e5</fpage>
            <pub-id pub-id-type="pmid">29278618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCarville</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Coleman</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Adderson</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Neel</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Gold</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Distinguishing Osteomyelitis From Ewing Sarcoma on Radiography and MRI.</article-title>
            <source>AJR Am J Roentgenol</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>205</volume>
            <issue>3</issue>
            <fpage>640</fpage>
            <page-range>640-50; quiz 651</page-range>
            <pub-id pub-id-type="pmid">26295653</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>The effect of pathological fractures on the prognosis of patients with osteosarcoma: a meta-analysis of 14 studies.</article-title>
            <source>Oncotarget</source>
            <year>2017</year>
            <month>Sep</month>
            <day>22</day>
            <volume>8</volume>
            <issue>42</issue>
            <fpage>73037</fpage>
            <page-range>73037-73049</page-range>
            <pub-id pub-id-type="pmid">29069847</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ong</surname>
                <given-names>ZY</given-names>
              </name>
              <name>
                <surname>Chai</surname>
                <given-names>HZ</given-names>
              </name>
              <name>
                <surname>How</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Koh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Low</surname>
                <given-names>TB</given-names>
              </name>
            </person-group>
            <article-title>A simplified approach to haemoptysis.</article-title>
            <source>Singapore Med J</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>57</volume>
            <issue>8</issue>
            <fpage>415</fpage>
            <page-range>415-8</page-range>
            <pub-id pub-id-type="pmid">27549136</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feng</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Teng</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Osteosarcoma of the spine: surgical treatment and outcomes.</article-title>
            <source>World J Surg Oncol</source>
            <year>2013</year>
            <month>Apr</month>
            <day>18</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>89</fpage>
            <pub-id pub-id-type="pmid">23597053</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Crockard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bunger</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Harms</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kawahara</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mazel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Melcher</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tomita</surname>
                <given-names>K</given-names>
              </name>
              <collab>Global Spine Tumor Study Group</collab>
            </person-group>
            <article-title>Review of metastatic spine tumour classification and indications for surgery: the consensus statement of the Global Spine Tumour Study Group.</article-title>
            <source>Eur Spine J</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>215</fpage>
            <page-range>215-22</page-range>
            <pub-id pub-id-type="pmid">20039084</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frezza</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Beale</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bomanji</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jay</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kalavrezos</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dileo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Whelan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Strauss</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Is [F-18]-fluorodeoxy-D-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment?</article-title>
            <source>BMC Cancer</source>
            <year>2014</year>
            <month>Jan</month>
            <day>15</day>
            <volume>14</volume>
            <fpage>23</fpage>
            <pub-id pub-id-type="pmid">24422949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nascimento</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Suchard</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hatem</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>de Abreu</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The role of magnetic resonance imaging in the evaluation of bone tumours and tumour-like lesions.</article-title>
            <source>Insights Imaging</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>419</fpage>
            <page-range>419-40</page-range>
            <pub-id pub-id-type="pmid">25005774</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nthumba</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Osteosarcoma of the jaws: a review of literature and a case report on synchronous multicentric osteosarcomas.</article-title>
            <source>World J Surg Oncol</source>
            <year>2012</year>
            <month>Nov</month>
            <day>12</day>
            <volume>10</volume>
            <fpage>240</fpage>
            <pub-id pub-id-type="pmid">23140538</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fernandes</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Natal</surname>
                <given-names>MRC</given-names>
              </name>
              <name>
                <surname>da Cruz</surname>
                <given-names>CLP</given-names>
              </name>
              <name>
                <surname>Nascif</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Tsuno</surname>
                <given-names>NSG</given-names>
              </name>
              <name>
                <surname>Tsuno</surname>
                <given-names>MY</given-names>
              </name>
            </person-group>
            <article-title>Primary osteosarcoma of the cranial vault.</article-title>
            <source>Radiol Bras</source>
            <year>2017</year>
            <season>Jul-Aug</season>
            <volume>50</volume>
            <issue>4</issue>
            <fpage>263</fpage>
            <page-range>263-265</page-range>
            <pub-id pub-id-type="pmid">28894335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kundu</surname>
                <given-names>ZS</given-names>
              </name>
            </person-group>
            <article-title>Classification, imaging, biopsy and staging of osteosarcoma.</article-title>
            <source>Indian J Orthop</source>
            <year>2014</year>
            <month>May</month>
            <volume>48</volume>
            <issue>3</issue>
            <fpage>238</fpage>
            <page-range>238-46</page-range>
            <pub-id pub-id-type="pmid">24932027</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sun</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>Analysis of imaging characteristics of primary malignant bone tumors in children.</article-title>
            <source>Oncol Lett</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>5801</fpage>
            <page-range>5801-5810</page-range>
            <pub-id pub-id-type="pmid">29113210</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gerrand</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Athanasou</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Brennan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Grimer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Judson</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Morland</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Peake</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Seddon</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Whelan</surname>
                <given-names>J</given-names>
              </name>
              <collab>British Sarcoma Group</collab>
            </person-group>
            <article-title>UK guidelines for the management of bone sarcomas.</article-title>
            <source>Clin Sarcoma Res</source>
            <year>2016</year>
            <volume>6</volume>
            <fpage>7</fpage>
            <pub-id pub-id-type="pmid">27148438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Seebacher</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Hornicek</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Duan</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Application of liquid biopsy in bone and soft tissue sarcomas: Present and future.</article-title>
            <source>Cancer Lett</source>
            <year>2018</year>
            <month>Dec</month>
            <day>28</day>
            <volume>439</volume>
            <fpage>66</fpage>
            <page-range>66-77</page-range>
            <pub-id pub-id-type="pmid">30223067</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baguley</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Prayuenyong</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Looking beyond the audiogram in ototoxicity associated with platinum-based chemotherapy.</article-title>
            <source>Cancer Chemother Pharmacol</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>85</volume>
            <issue>2</issue>
            <fpage>245</fpage>
            <page-range>245-250</page-range>
            <pub-id pub-id-type="pmid">31865419</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ando</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Heymann</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Stresing</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mori</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>R&#x000e9;dini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Heymann</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Current therapeutic strategies and novel approaches in osteosarcoma.</article-title>
            <source>Cancers (Basel)</source>
            <year>2013</year>
            <month>May</month>
            <day>24</day>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>591</fpage>
            <page-range>591-616</page-range>
            <pub-id pub-id-type="pmid">24216993</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bielack</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Hecker-Nolting</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Blattmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kager</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Advances in the management of osteosarcoma.</article-title>
            <source>F1000Res</source>
            <year>2016</year>
            <volume>5</volume>
            <fpage>2767</fpage>
            <pub-id pub-id-type="pmid">27990273</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Misaghi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Goldin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Awad</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kulidjian</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Osteosarcoma: a comprehensive review.</article-title>
            <source>SICOT J</source>
            <year>2018</year>
            <volume>4</volume>
            <fpage>12</fpage>
            <pub-id pub-id-type="pmid">29629690</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Biermann</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Chow</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Lucas</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Adkins</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Agulnik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Benjamin</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Brigman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Budd</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Curry</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Didwania</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fabbri</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hornicek</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Kuechle</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Lindskog</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mayerson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McGarry</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Million</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Movva</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>O'Donnell</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Randall</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Santana</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Satcher</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Thornton</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Villalobos</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bergman</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Scavone</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>NCCN Guidelines Insights: Bone Cancer, Version 2.2017.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>155</fpage>
            <page-range>155-167</page-range>
            <pub-id pub-id-type="pmid">28188186</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Casali</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Bielack</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Abecassis</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Aro</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Biagini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bonvalot</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Boukovinas</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bovee</surname>
                <given-names>JVMG</given-names>
              </name>
              <name>
                <surname>Brennan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Brodowicz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Broto</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Brugi&#x000e8;res</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Buonadonna</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>De &#x000c1;lava</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dei Tos</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Del Muro</surname>
                <given-names>XG</given-names>
              </name>
              <name>
                <surname>Dileo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dhooge</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Eriksson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fagioli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fedenko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ferraresi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Frezza</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Gaspar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gasperoni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gelderblom</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gil</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Grignani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gronchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Haas</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Hassan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hecker-Nolting</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hohenberger</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Issels</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Joensuu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Judson</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Jutte</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kaal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kager</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kasper</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kopeckova</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kr&#x000e1;korov&#x000e1;</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Ladenstein</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Le Cesne</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lugowska</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Merimsky</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Montemurro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morland</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pantaleo</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Piana</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Picci</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Piperno-Neumann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pousa</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Reichardt</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Rutkowski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Safwat</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Sch&#x000f6;ffski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sleijfer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stacchiotti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Strauss</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Sundby Hall</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Unk</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Van Coevorden</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>van der Graaf</surname>
                <given-names>WTA</given-names>
              </name>
              <name>
                <surname>Whelan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wardelmann</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zaikova</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Blay</surname>
                <given-names>JY</given-names>
              </name>
              <collab>ESMO Guidelines Committee, PaedCan and ERN EURACAN</collab>
            </person-group>
            <article-title>Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.</article-title>
            <source>Ann Oncol</source>
            <year>2018</year>
            <month>Oct</month>
            <day>01</day>
            <volume>29</volume>
            <issue>Suppl 4</issue>
            <fpage>iv79</fpage>
            <page-range>iv79-iv95</page-range>
            <pub-id pub-id-type="pmid">30285218</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ashana</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Moretti</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Lackman</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>The relation of tumour necrosis and survival in patients with osteosarcoma.</article-title>
            <source>Int Orthop</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>35</volume>
            <issue>12</issue>
            <fpage>1847</fpage>
            <page-range>1847-53</page-range>
            <pub-id pub-id-type="pmid">21359502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huvos</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Rosen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Marcove</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement.</article-title>
            <source>Arch Pathol Lab Med</source>
            <year>1977</year>
            <month>Jan</month>
            <volume>101</volume>
            <issue>1</issue>
            <fpage>14</fpage>
            <page-range>14-8</page-range>
            <pub-id pub-id-type="pmid">299812</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Marcove</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Caparros</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nirenberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kosloff</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Huvos</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery.</article-title>
            <source>Cancer</source>
            <year>1979</year>
            <month>Jun</month>
            <volume>43</volume>
            <issue>6</issue>
            <fpage>2163</fpage>
            <page-range>2163-77</page-range>
            <pub-id pub-id-type="pmid">88251</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shepperd</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gon&#x000e7;alves-Bradley</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Straus</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Wee</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Hospital at home: home-based end-of-life care.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2016</year>
            <month>Feb</month>
            <day>18</day>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>CD009231</fpage>
            <pub-id pub-id-type="pmid">26887902</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barnes</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Smallwood</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Manser</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2016</year>
            <month>Mar</month>
            <day>31</day>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>CD011008</fpage>
            <pub-id pub-id-type="pmid">27030166</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bertrand</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Cruz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Binitie</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Cheong</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Letson</surname>
                <given-names>GD</given-names>
              </name>
            </person-group>
            <article-title>Do Surgical Margins Affect Local Recurrence and Survival in Extremity, Nonmetastatic, High-grade Osteosarcoma?</article-title>
            <source>Clin Orthop Relat Res</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>474</volume>
            <issue>3</issue>
            <fpage>677</fpage>
            <page-range>677-83</page-range>
            <pub-id pub-id-type="pmid">26013153</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salzer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Knahr</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kotz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kristen</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Treatment of osteosarcomata of the distal femur by rotation-plasty.</article-title>
            <source>Arch Orthop Trauma Surg (1978)</source>
            <year>1981</year>
            <volume>99</volume>
            <issue>2</issue>
            <fpage>131</fpage>
            <page-range>131-6</page-range>
            <pub-id pub-id-type="pmid">6947721</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Alassaf</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Harrop</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Kiefer</surname>
                <given-names>GN</given-names>
              </name>
            </person-group>
            <article-title>Principles of rotationplasty.</article-title>
            <source>J Am Acad Orthop Surg</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>20</volume>
            <issue>10</issue>
            <fpage>657</fpage>
            <page-range>657-67</page-range>
            <pub-id pub-id-type="pmid">23027695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Donnell</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Compressive osseointegration of tibial implants in primary cancer reconstruction.</article-title>
            <source>Clin Orthop Relat Res</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>467</volume>
            <issue>11</issue>
            <fpage>2807</fpage>
            <page-range>2807-12</page-range>
            <pub-id pub-id-type="pmid">19653050</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>B&#x000f6;hler</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Br&#x000f6;nimann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaider</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Puchner</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Sigmund</surname>
                <given-names>IK</given-names>
              </name>
              <name>
                <surname>Windhager</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Funovics</surname>
                <given-names>PT</given-names>
              </name>
            </person-group>
            <article-title>Surgical and Functional Outcome after Endoprosthetic Reconstruction in Patients with Osteosarcoma of the Humerus.</article-title>
            <source>Sci Rep</source>
            <year>2018</year>
            <month>Nov</month>
            <day>08</day>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>16148</fpage>
            <pub-id pub-id-type="pmid">30410099</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Xiong</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Reconstruction of bone defect with allograft and retrograde intramedullary nail for distal tibia osteosarcoma.</article-title>
            <source>Foot Ankle Surg</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>149</fpage>
            <page-range>149-153</page-range>
            <pub-id pub-id-type="pmid">29409222</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Rastogi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bakhshi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rath</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Julka</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Laviraj</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Role of extracorporeal irradiation in malignant bone tumors.</article-title>
            <source>Indian J Cancer</source>
            <year>2013</year>
            <season>Oct-Dec</season>
            <volume>50</volume>
            <issue>4</issue>
            <fpage>306</fpage>
            <page-range>306-9</page-range>
            <pub-id pub-id-type="pmid">24369205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hong</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stalley</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pendlebury</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ahern</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ralston</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Estoesta</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Barrett</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Extracorporeal irradiation for malignant bone tumors.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2001</year>
            <month>Jun</month>
            <day>01</day>
            <volume>50</volume>
            <issue>2</issue>
            <fpage>441</fpage>
            <page-range>441-7</page-range>
            <pub-id pub-id-type="pmid">11380232</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwarz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bruland</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Cassoni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schomberg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bielack</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The role of radiotherapy in oseosarcoma.</article-title>
            <source>Cancer Treat Res</source>
            <year>2009</year>
            <volume>152</volume>
            <fpage>147</fpage>
            <page-range>147-64</page-range>
            <pub-id pub-id-type="pmid">20213389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marina</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Smeland</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bielack</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jovic</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Krailo</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Hook</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Arndt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>van den Berg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Brennan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Brichard</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>KLB</given-names>
              </name>
              <name>
                <surname>Butterfass-Bahloul</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Calaminus</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Daldrup-Link</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Eriksson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gebhardt</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Gelderblom</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gerss</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Goldsby</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Goorin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gorlick</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Grier</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Hale</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Hardes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Helmke</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hogendoorn</surname>
                <given-names>PCW</given-names>
              </name>
              <name>
                <surname>Isakoff</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Janeway</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>J&#x000fc;rgens</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kager</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>K&#x000fc;hne</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Leavey</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Lessnick</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Mascarenhas</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Meyers</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Mottl</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nathrath</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Papai</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Randall</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Reichardt</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Renard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Safwat</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>MCG</given-names>
              </name>
              <name>
                <surname>Strauss</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Teot</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Werner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sydes</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Whelan</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>17</volume>
            <issue>10</issue>
            <fpage>1396</fpage>
            <page-range>1396-1408</page-range>
            <pub-id pub-id-type="pmid">27569442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smeland</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bielack</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Whelan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hogendoorn</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Krailo</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Gorlick</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Janeway</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Ingleby</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Anninga</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Antal</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Arndt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>KLB</given-names>
              </name>
              <name>
                <surname>Butterfass-Bahloul</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Calaminus</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Capra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dhooge</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Eriksson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Flanagan</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Friedel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gebhardt</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Gelderblom</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Goldsby</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Grier</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Grimer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Hecker-Nolting</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sundby Hall</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Isakoff</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Jovic</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>K&#x000fc;hne</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kager</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>von Kalle</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kabickova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Leavey</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Lessnick</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Mascarenhas</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mayer-Steinacker</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Meyers</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Nagarajan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Randall</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Reichardt</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Renard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rechnitzer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Strauss</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Teot</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Timmermann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sydes</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Marina</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort.</article-title>
            <source>Eur J Cancer</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>109</volume>
            <fpage>36</fpage>
            <page-range>36-50</page-range>
            <pub-id pub-id-type="pmid">30685685</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chou</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Kleinerman</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Krailo</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Betcher</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Healey</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Conrad</surname>
                <given-names>EU</given-names>
              </name>
              <name>
                <surname>Nieder</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Weiner</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Womer</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Meyers</surname>
                <given-names>PA</given-names>
              </name>
              <collab>Children's Oncology Group</collab>
            </person-group>
            <article-title>Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.</article-title>
            <source>Cancer</source>
            <year>2009</year>
            <month>Nov</month>
            <day>15</day>
            <volume>115</volume>
            <issue>22</issue>
            <fpage>5339</fpage>
            <page-range>5339-48</page-range>
            <pub-id pub-id-type="pmid">19637348</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyers</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Krailo</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Healey</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Betcher</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ferguson</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Gebhardt</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Goorin</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kleinerman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Nadel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nieder</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Siegal</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Weiner</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Womer</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Grier</surname>
                <given-names>HE</given-names>
              </name>
              <collab>Children's Oncology Group</collab>
            </person-group>
            <article-title>Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.</article-title>
            <source>J Clin Oncol</source>
            <year>2008</year>
            <month>Feb</month>
            <day>01</day>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>633</fpage>
            <page-range>633-8</page-range>
            <pub-id pub-id-type="pmid">18235123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jaffe</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Puri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gelderblom</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Osteosarcoma: evolution of treatment paradigms.</article-title>
            <source>Sarcoma</source>
            <year>2013</year>
            <volume>2013</volume>
            <fpage>203531</fpage>
            <pub-id pub-id-type="pmid">23781130</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Kane</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Cadoo</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Emerson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dervan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>O'Keane</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hurson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>O'Toole</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dudeney</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kavanagh</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Eustace</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carney</surname>
                <given-names>DN</given-names>
              </name>
            </person-group>
            <article-title>Perioperative chemotherapy in the treatment of osteosarcoma: a 26-year single institution review.</article-title>
            <source>Clin Sarcoma Res</source>
            <year>2015</year>
            <volume>5</volume>
            <fpage>17</fpage>
            <pub-id pub-id-type="pmid">26175892</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bacci</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Forni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Longhi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bertoni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mercuri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Donati</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Capanna</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bernini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Briccoli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Setola</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Versari</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome.</article-title>
            <source>J Pediatr Hematol Oncol</source>
            <year>2003</year>
            <month>Nov</month>
            <volume>25</volume>
            <issue>11</issue>
            <fpage>845</fpage>
            <page-range>845-53</page-range>
            <pub-id pub-id-type="pmid">14608193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Prediction and evaluation of neoadjuvant chemotherapy using the dual mechanisms of <sup>99m</sup>Tc-MIBI scintigraphy in patients with osteosarcoma.</article-title>
            <source>J Bone Oncol</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>17</volume>
            <fpage>100250</fpage>
            <pub-id pub-id-type="pmid">31372331</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benjamin</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Livingston</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Ravi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Chemotherapy for bone sarcomas in adults: the MD anderson experience.</article-title>
            <source>Am Soc Clin Oncol Educ Book</source>
            <year>2015</year>
            <fpage>e656</fpage>
            <page-range>e656-60</page-range>
            <pub-id pub-id-type="pmid">25993237</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Niu</surname>
                <given-names>XH</given-names>
              </name>
            </person-group>
            <article-title>[Updates and interpretations of 2017 NCCN guidelines for bone cancer].</article-title>
            <source>Zhonghua Wai Ke Za Zhi</source>
            <year>2017</year>
            <month>Jan</month>
            <day>01</day>
            <volume>55</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <page-range>41-43</page-range>
            <pub-id pub-id-type="pmid">28056253</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xiao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>The role of chemotherapy for metastatic, relapsed and refractory osteosarcoma.</article-title>
            <source>Paediatr Drugs</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>16</volume>
            <issue>6</issue>
            <fpage>503</fpage>
            <page-range>503-12</page-range>
            <pub-id pub-id-type="pmid">25392156</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raciborska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bilska</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Sorafenib in patients with progressed and refractory bone tumors.</article-title>
            <source>Med Oncol</source>
            <year>2018</year>
            <month>Aug</month>
            <day>16</day>
            <volume>35</volume>
            <issue>10</issue>
            <fpage>126</fpage>
            <pub-id pub-id-type="pmid">30116912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coventon</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A review of the mechanism of action and clinical applications of sorafenib in advanced osteosarcoma.</article-title>
            <source>J Bone Oncol</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>8</volume>
            <fpage>4</fpage>
            <page-range>4-7</page-range>
            <pub-id pub-id-type="pmid">28828294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grignani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Palmerini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ferraresi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>D'Ambrosio</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bertulli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Asaftei</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Tamburini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pignochino</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sangiolo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Marchesi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Capozzi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Biagini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gambarotti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fagioli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Casali</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Picci</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aglietta</surname>
                <given-names>M</given-names>
              </name>
              <collab>Italian Sarcoma Group</collab>
            </person-group>
            <article-title>Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>98</fpage>
            <page-range>98-107</page-range>
            <pub-id pub-id-type="pmid">25498219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodr&#x000ed;guez-Galindo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Daw</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Kaste</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Dome</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Pappo</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Pratt</surname>
                <given-names>CB</given-names>
              </name>
            </person-group>
            <article-title>Treatment of refractory osteosarcoma with fractionated cyclophosphamide and etoposide.</article-title>
            <source>J Pediatr Hematol Oncol</source>
            <year>2002</year>
            <month>May</month>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>250</fpage>
            <page-range>250-5</page-range>
            <pub-id pub-id-type="pmid">11972091</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Longo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lutz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Johnstone</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Samarium-153-ethylene diamine tetramethylene phosphonate, a beta-emitting bone-targeted radiopharmaceutical, useful for patients with osteoblastic bone metastases.</article-title>
            <source>Cancer Manag Res</source>
            <year>2013</year>
            <volume>5</volume>
            <fpage>235</fpage>
            <page-range>235-42</page-range>
            <pub-id pub-id-type="pmid">23976864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bai</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Risk and clinicopathological features of osteosarcoma metastasis to the lung: A population-based study.</article-title>
            <source>J Bone Oncol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>16</volume>
            <fpage>100230</fpage>
            <pub-id pub-id-type="pmid">30923668</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kamar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Progress in the chemotherapeutic treatment of osteosarcoma.</article-title>
            <source>Oncol Lett</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>16</volume>
            <issue>5</issue>
            <fpage>6228</fpage>
            <page-range>6228-6237</page-range>
            <pub-id pub-id-type="pmid">30405759</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loeb</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Garrett-Mayer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hobbs</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Prideaux</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Sgouros</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shokek</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Wharam</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma.</article-title>
            <source>Cancer</source>
            <year>2009</year>
            <month>Jun</month>
            <day>01</day>
            <volume>115</volume>
            <issue>11</issue>
            <fpage>2514</fpage>
            <page-range>2514-22</page-range>
            <pub-id pub-id-type="pmid">19338063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wedekind</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Cripe</surname>
                <given-names>TP</given-names>
              </name>
            </person-group>
            <article-title>Immunotherapy for osteosarcoma: Where do we go from here?</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>65</volume>
            <issue>9</issue>
            <fpage>e27227</fpage>
            <pub-id pub-id-type="pmid">29923370</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salmen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Banys-Paluchowski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fehm</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Bone-Targeted Therapy.</article-title>
            <source>Geburtshilfe Frauenheilkd</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>75</volume>
            <issue>6</issue>
            <fpage>584</fpage>
            <page-range>584-587</page-range>
            <pub-id pub-id-type="pmid">26166839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farrell</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Karpeisky</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thamm</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Zinnen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Bisphosphonate conjugation for bone specific drug targeting.</article-title>
            <source>Bone Rep</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>9</volume>
            <fpage>47</fpage>
            <page-range>47-60</page-range>
            <pub-id pub-id-type="pmid">29992180</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r85">
          <label>85</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Moretti</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Ashana</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Lackman</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Impact of close surgical margin on local recurrence and survival in osteosarcoma.</article-title>
            <source>Int Orthop</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>36</volume>
            <issue>1</issue>
            <fpage>131</fpage>
            <page-range>131-7</page-range>
            <pub-id pub-id-type="pmid">21404025</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r86">
          <label>86</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bispo J&#x000fa;nior</surname>
                <given-names>RZ</given-names>
              </name>
              <name>
                <surname>Camargo</surname>
                <given-names>OP</given-names>
              </name>
            </person-group>
            <article-title>Prognostic factors in the survival of patients diagnosed with primary non-metastatic osteosarcoma with a poor response to neoadjuvant chemotherapy.</article-title>
            <source>Clinics (Sao Paulo)</source>
            <year>2009</year>
            <volume>64</volume>
            <issue>12</issue>
            <fpage>1177</fpage>
            <page-range>1177-86</page-range>
            <pub-id pub-id-type="pmid">20037705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r87">
          <label>87</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wadhwa</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Osteosarcoma: Diagnostic dilemmas in histopathology and prognostic factors.</article-title>
            <source>Indian J Orthop</source>
            <year>2014</year>
            <month>May</month>
            <volume>48</volume>
            <issue>3</issue>
            <fpage>247</fpage>
            <page-range>247-54</page-range>
            <pub-id pub-id-type="pmid">24932029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zum&#x000e1;rraga</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Baptista</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Rosa</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Caiero</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Camargo</surname>
                <given-names>OP</given-names>
              </name>
            </person-group>
            <article-title>SERUM VALUES OF ALKALINE PHOSPHATASE AND LACTATE DEHYDROGENASE IN OSTEOSARCOMA.</article-title>
            <source>Acta Ortop Bras</source>
            <year>2016</year>
            <season>May-Jun</season>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>142</fpage>
            <page-range>142-6</page-range>
            <pub-id pub-id-type="pmid">27217815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r89">
          <label>89</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Horvai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Unni</surname>
                <given-names>KK</given-names>
              </name>
            </person-group>
            <article-title>Premalignant conditions of bone.</article-title>
            <source>J Orthop Sci</source>
            <year>2006</year>
            <month>Jul</month>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>412</fpage>
            <page-range>412-23</page-range>
            <pub-id pub-id-type="pmid">16897210</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r90">
          <label>90</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Unni</surname>
                <given-names>KK</given-names>
              </name>
            </person-group>
            <article-title>Osteosarcoma of bone.</article-title>
            <source>J Orthop Sci</source>
            <year>1998</year>
            <volume>3</volume>
            <issue>5</issue>
            <fpage>287</fpage>
            <page-range>287-94</page-range>
            <pub-id pub-id-type="pmid">9732564</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r91">
          <label>91</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carrle</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bielack</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Current strategies of chemotherapy in osteosarcoma.</article-title>
            <source>Int Orthop</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>30</volume>
            <issue>6</issue>
            <fpage>445</fpage>
            <page-range>445-51</page-range>
            <pub-id pub-id-type="pmid">16896870</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r92">
          <label>92</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McHugh</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Herman</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Adsay</surname>
                <given-names>NV</given-names>
              </name>
              <name>
                <surname>Rabah</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lucas</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Primary versus radiation-associated craniofacial osteosarcoma: Biologic and clinicopathologic comparisons.</article-title>
            <source>Cancer</source>
            <year>2006</year>
            <month>Aug</month>
            <day>01</day>
            <volume>107</volume>
            <issue>3</issue>
            <fpage>554</fpage>
            <page-range>554-62</page-range>
            <pub-id pub-id-type="pmid">16795069</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r93">
          <label>93</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Prognostic value of pre-treatment Naples prognostic score (NPS) in patients with osteosarcoma.</article-title>
            <source>World J Surg Oncol</source>
            <year>2020</year>
            <month>Jan</month>
            <day>30</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>24</fpage>
            <pub-id pub-id-type="pmid">32000789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r94">
          <label>94</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jettoo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gerrand</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Rankin</surname>
                <given-names>KS</given-names>
              </name>
            </person-group>
            <article-title>Role of routine blood tests for predicting clinical outcomes in osteosarcoma patients.</article-title>
            <source>J Orthop Surg (Hong Kong)</source>
            <year>2019</year>
            <season>May-Aug</season>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>2309499019838293</fpage>
            <pub-id pub-id-type="pmid">30909848</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r95">
          <label>95</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jawad</surname>
                <given-names>MU</given-names>
              </name>
              <name>
                <surname>Scully</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>In brief: classifications in brief: Mirels' classification: metastatic disease in long bones and impending pathologic fracture.</article-title>
            <source>Clin Orthop Relat Res</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>468</volume>
            <issue>10</issue>
            <fpage>2825</fpage>
            <page-range>2825-7</page-range>
            <pub-id pub-id-type="pmid">20352387</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r96">
          <label>96</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ormsby</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Leong</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Swaminathan</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>The current status of prophylactic femoral intramedullary nailing for metastatic cancer.</article-title>
            <source>Ecancermedicalscience</source>
            <year>2016</year>
            <volume>10</volume>
            <fpage>698</fpage>
            <pub-id pub-id-type="pmid">28105069</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r97">
          <label>97</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saumet</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Deschamps</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Marec-Berard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gaspar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Corradini</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Petit</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sirvent</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Brugi&#x000e8;res</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Radiofrequency ablation of metastases from osteosarcoma in patients under 25 years: the SCFE experience.</article-title>
            <source>Pediatr Hematol Oncol</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <page-range>41-9</page-range>
            <pub-id pub-id-type="pmid">25007012</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r98">
          <label>98</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scully</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Ghert</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Zurakowski</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Gebhardt</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Pathologic fracture in osteosarcoma : prognostic importance and treatment implications.</article-title>
            <source>J Bone Joint Surg Am</source>
            <year>2002</year>
            <month>Jan</month>
            <volume>84</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <page-range>49-57</page-range>
            <pub-id pub-id-type="pmid">11792779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r99">
          <label>99</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pflugmacher</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Beth</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schroeder</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Schaser</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Melcher</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Balloon kyphoplasty for the treatment of pathological fractures in the thoracic and lumbar spine caused by metastasis: one-year follow-up.</article-title>
            <source>Acta Radiol</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>48</volume>
            <issue>1</issue>
            <fpage>89</fpage>
            <page-range>89-95</page-range>
            <pub-id pub-id-type="pmid">17325932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r100">
          <label>100</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>P&#x000f6;nisch</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Niederwieser</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>[Late effects after chemotherapy].</article-title>
            <source>Internist (Berl)</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>47</volume>
            <issue>3</issue>
            <fpage>266</fpage>
            <page-range>266-8, 270-72</page-range>
            <pub-id pub-id-type="pmid">16470355</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r101">
          <label>101</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ng</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Kenney</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Gilbert</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Travis</surname>
                <given-names>LB</given-names>
              </name>
            </person-group>
            <article-title>Secondary malignancies across the age spectrum.</article-title>
            <source>Semin Radiat Oncol</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>67</fpage>
            <page-range>67-78</page-range>
            <pub-id pub-id-type="pmid">19959033</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r102">
          <label>102</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhou</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Hao</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Advances in targeted therapy for osteosarcoma.</article-title>
            <source>Discov Med</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>17</volume>
            <issue>96</issue>
            <fpage>301</fpage>
            <page-range>301-7</page-range>
            <pub-id pub-id-type="pmid">24979249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r103">
          <label>103</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abarrategi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tornin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Martinez-Cruzado</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martinez-Campos</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rodrigo</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Baldini</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Garcia-Castro</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies.</article-title>
            <source>Stem Cells Int</source>
            <year>2016</year>
            <volume>2016</volume>
            <fpage>3631764</fpage>
            <pub-id pub-id-type="pmid">27366153</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r104">
          <label>104</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ayerza</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Farfalli</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Aponte-Tinao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Muscolo</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Does increased rate of limb-sparing surgery affect survival in osteosarcoma?</article-title>
            <source>Clin Orthop Relat Res</source>
            <year>2010</year>
            <month>Nov</month>
            <volume>468</volume>
            <issue>11</issue>
            <fpage>2854</fpage>
            <page-range>2854-9</page-range>
            <pub-id pub-id-type="pmid">20559766</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r105">
          <label>105</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reed</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Binitie</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Steppan</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Brohl</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Shinohara</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Bridge</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Loeb</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Borinstein</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Isakoff</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Treatment pathway of bone sarcoma in children, adolescents, and young adults.</article-title>
            <source>Cancer</source>
            <year>2017</year>
            <month>Jun</month>
            <day>15</day>
            <volume>123</volume>
            <issue>12</issue>
            <fpage>2206</fpage>
            <page-range>2206-2218</page-range>
            <pub-id pub-id-type="pmid">28323337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26391.r106">
          <label>106</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andritsch</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Beishon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bielack</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bonvalot</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Casali</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Crul</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Delgado Bolton</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Donati</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Douis</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Haas</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hogendoorn</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kozhaeva</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Lavender</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lovey</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Negrouk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Roca</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>de Lempdes</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Saarto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>van Berck</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Vassal</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wartenberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yared</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Naredi</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>ECCO Essential Requirements for Quality Cancer Care: Soft Tissue Sarcoma in Adults and Bone Sarcoma. A critical review.</article-title>
            <source>Crit Rev Oncol Hematol</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>110</volume>
            <fpage>94</fpage>
            <page-range>94-105</page-range>
            <pub-id pub-id-type="pmid">28109409</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
